- •Uveitis
- •Foreword
- •Preface
- •Dedication
- •Acknowledgments
- •Elements of the Immune System and Concepts of Intraocular Inflammatory Disease Pathogenesis
- •Elements of the immune system
- •Macrophages/monocytes
- •Dendritic cells
- •T cells
- •Major subsets of T cells
- •Cytokines
- •T-cell subsets
- •T-regulatory cells
- •T-cell receptor
- •Chemokines
- •Thymic expression and central immune tolerance
- •B cells
- •Classes of Immunoglobulin
- •Other cells
- •Mast Cells
- •Eosinophils
- •Neutrophils
- •Resident Ocular Cells
- •Complement system
- •Cellular interactions: hypersensitivity reactions
- •Classic immune hypersensitivity reactions
- •Type I
- •Type II
- •Type III
- •Type IV
- •Type V
- •Concepts of disease pathogenesis
- •Immune characteristics of the eye
- •Absence of lymphatic drainage
- •Intraocular microenvironment
- •Anterior Chamber-Associated Immune Deviation (ACAID)
- •Fas-Fas Ligand Interactions and Programmed Cell Death (Apoptosis)
- •Resident Ocular Cells and Immune System
- •Cytokines and Chemokines and the Eye
- •Oral Tolerance
- •Choroidal circulation and anatomy
- •Retina
- •Immunogenetics
- •Class I antigens
- •Class II and class III antigens
- •Histocompatibility lymphocyte antigens
- •Single-nucleotide polymorphisms (SNPs)
- •Epigenetics
- •Immune complex-mediated disease
- •Gene expression profiling
- •Tissue damage in the eye
- •T-cell responses and autoimmunity
- •T-cell receptor and the expression of disease
- •Ocular autoimmunity
- •Uveitogenic antigens
- •Retinal S-Antigen (Arrestin)
- •Interphotoreceptor Retinoid-Binding Protein
- •Recoverin
- •Bovine Melanin Protein
- •Rhodopsin
- •Phosducin
- •Tyrosinase
- •Other Antigens
- •Endotoxin and Other Bacterial Antigens
- •Importance of Antigen Studies
- •Cell adhesion molecules and their role in lymphocyte homing and in disease
- •Immune responses to invading viruses and parasites
- •Suggested Readings
- •References
- •Medical History in the Patient with Uveitis
- •References
- •Sample Uveitis Questionnaire
- •FAMILY HISTORY
- •SOCIAL HISTORY
- •PERSONAL MEDICAL HISTORY
- •MEDICAL HISTORY
- •Examination of the Patient with Uveitis
- •Visual acuity
- •External examination
- •Pupils and extraocular muscles
- •Intraocular pressure measurement
- •Slit-lamp biomicroscopy
- •Conjunctiva
- •Cornea
- •Keratic Precipitates
- •Other Corneal Findings
- •Anterior chamber
- •Iris
- •Anterior chamber angle
- •Lens
- •Vitreous
- •Retina and choroid
- •Optic nerve
- •References
- •Development of a Differential Diagnosis
- •Forming a differential diagnosis
- •Classifying uveitis
- •Is the disease acute or chronic?
- •Is the inflammation granulomatous or nongranulomatous?
- •Is the disease unilateral or bilateral?
- •Where is the inflammation located in the eye?
- •What are the demographics of the patient?
- •What associated symptoms does the patient have?
- •What associated signs are present on physical examination?
- •What is the time course of the disease and response to previous therapy?
- •Case 4-1
- •Case 4-2
- •References
- •Diagnostic Testing
- •Pretest likelihood of disease
- •Receiver operating characteristic (ROC) curve
- •Diagnostic tests for uveitis
- •Laboratory tests
- •Image analysis
- •Skin testing
- •Tissue samples
- •Ancillary ophthalmic tests
- •Electrophysiology
- •Laser interferometry
- •Fluorescein angiography
- •Indocyanine green
- •Laser flare photometry
- •Optical coherence tomography
- •High-frequency ultrasound biomicroscopy and multifrequency ultrasound
- •Fundus autofluorescence
- •Other diagnostic tests
- •Polymerase chain reaction (PCR)
- •Rapid tests for herpes simplex and herpes zoster
- •Bone mineral density studies
- •Genetic testing for steroid-induced glaucoma
- •Neurologic tests
- •References
- •Evidence-Based Medicine in Uveitis
- •Study design
- •Clinical trials in uveitis
- •References
- •Philosophy, Goals, and Approaches to Medical Therapy
- •Goals and philosophy
- •Pain, photophobia, and discomfort
- •Degree and location of inflammatory disease
- •Evaluation of visual acuity and prospect of reversibility
- •Follow-up procedures and standardization of observations
- •General health and age of patient
- •Patient reliability, preferences, and understanding
- •Nonsurgical therapeutic options
- •Corticosteroids
- •Mode of Action
- •Preparations, Dosage Schedules, and Complications
- •Ozurdex.
- •Secondary Effects
- •Cytotoxic agents
- •Alkylating agents
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Antimetabolites
- •Azathioprine
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Mycophenolate mofetil
- •Methotrexate
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Ciclosporin
- •Mode of Action
- •Dosages and Indications
- •Secondary Effects
- •Tacrolimus
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Lx 211 (Voclosporin)
- •Rapamycin
- •Mode of Action
- •Indications and Dosages
- •Toxicity
- •Antibodies and monoclonal antibodies
- •Daclizumab
- •Etanercept
- •Infliximab (Remicade)
- •Adalimumab (Humira)
- •Efalizumab (Raptiva)
- •Rituximab (Rituxan)
- •Anakinra (Kineret)
- •Alemtuzumab (Campath-1H)
- •Abatacept (Orencia)
- •Intravenous immunoglobulin therapy
- •Oral tolerance
- •Interferon-α
- •Antiviral therapy
- •Aciclovir
- •Ganciclovir
- •Valaciclovir
- •Famciclovir
- •Foscarnet
- •Combined ganciclovir and foscarnet
- •Cidofovir
- •Fomivirsen
- •Colchicine
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Mydriatic and cycloplegic agents
- •Antitoxoplasmosis therapy
- •Other therapeutic approaches
- •Immunostimulators
- •Plasmapheresis
- •Nonsteroidal antiinflammatory agents
- •References
- •Role of Surgery in the Patient with Uveitis
- •Considerations
- •Removal of band keratopathy
- •Corneal transplantation
- •Cataract surgery
- •Glaucoma surgery
- •Treatment of vitreoretinal disease
- •Laser treatment
- •Photodynamic therapy
- •Diagnostic surgery
- •Anterior chamber paracentesis
- •Chorioretinal biopsy
- •Subretinal surgery
- •Case 8-1
- •References
- •Bacterial and Fungal Diseases
- •Introduction
- •Leprosy
- •Clinical findings
- •Immunology and pathology
- •Therapy
- •Tuberculosis
- •Systemic disease
- •Ocular disease
- •Diagnosis
- •Therapy
- •Other bacterial infections
- •Brucellosis
- •Whipple’s disease
- •Treatment and prognosis
- •Chronic granulomatous disease
- •Fungal disease
- •Neuroretinitis
- •References
- •Spirochetal Diseases
- •Spirochetal infections and the eye
- •Spirochetes
- •Definition
- •Venereal treponemal diseases
- •Syphilis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Primary syphilis.
- •Secondary syphilis.
- •Latent syphilis.
- •Tertiary syphilis.
- •Benign tertiary syphilis.
- •Cardiovascular syphilis.
- •Neurosyphilis.
- •Congenital syphilis.
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •General recommendations.
- •Approach to Syphilis in Patients with AIDS
- •Nonvenereal treponematoses
- •Endemic syphilis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Yaws and pinta
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Borrelia infection
- •Lyme disease
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Relapsing fever
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Leptospirosis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Weil’s disease
- •Diagnosis
- •Prognosis
- •Treatment
- •Case 10-1
- •References
- •Acquired Immunodeficiency Syndrome
- •Human immunodeficiency virus
- •Epidemiology
- •Diagnosis
- •HIV disease
- •HIV therapy
- •Ocular manifestations of HIV infection
- •Ocular infection
- •Cytomegalovirus retinitis
- •Progression
- •CMV retinitis in the era of highly active antiretroviral therapy
- •Treatment
- •Intravitreal ganciclovir implant
- •Current therapeutic approach to CMV retinitis in the era of HAART
- •Retinal detachment
- •Prognosis
- •Immune recovery uveitis
- •Herpes zoster
- •Pneumocystis jirovecii choroiditis
- •Mycobacterium avium-intracellulare choroiditis
- •Other diseases
- •Drug-related ocular inflammation
- •Case 11-1
- •Case 11-2
- •References
- •Acute retinal necrosis
- •Epidemiology
- •Clinical features
- •Etiology
- •Differential diagnosis
- •Therapy
- •Progressive outer retinal necrosis
- •Diagnosis
- •Differential diagnosis
- •Etiology
- •Therapy
- •Case 12-1
- •Case 12-2
- •References
- •Other Viral Diseases
- •Herpes simplex virus kerititis and keratouveitis
- •Pathogenesis
- •Diagnosis
- •Treatment
- •Herpes zoster ophthalmicus
- •Treatment
- •West Nile virus
- •Epidemiology
- •Diagnosis
- •Clinical description
- •Ophthalmic manifestations
- •Treatment
- •Prognosis
- •Other viral infections
- •Human T-lymphotropic virus type I
- •Case 13-1
- •References
- •Ocular Toxoplasmosis
- •Organism
- •Clinical manifestations
- •Systemic
- •Ocular
- •Decreased Vision
- •Loss of Vision
- •Effects in immunocompromised host
- •Histopathology and immune factors
- •Immune response
- •Inflammatory response
- •Methods of diagnosis
- •Pregnancy
- •Other methods
- •Congenital versus acquired disease
- •Therapy
- •Additional therapeutic approaches
- •Case 14-1
- •Case 14-2
- •Case 14-3
- •Case 14-4
- •References
- •Ocular Histoplasmosis
- •Systemic findings
- •Ocular appearance
- •‘Histo’ spots
- •Maculopathy
- •Peripapillary pigment changes
- •Clear vitreous
- •Etiology and immunology
- •Nonsurgical therapies
- •Laser therapy
- •Subretinal surgery
- •References
- •Toxocara canis
- •Ocular manifestations
- •Histopathology and immune factors
- •Enzyme-linked immunoabsorbent assay
- •Treatment
- •Case 16-1
- •References
- •Onchocerciasis and Other Parasitic Diseases
- •Onchocerciasis
- •Clinical appearance
- •Immune characteristics
- •Therapy
- •Giardiasis
- •Ophthalmomyiasis
- •Cysticercosis
- •Caterpillar hairs
- •Amebiasis
- •Diffuse unilateral subacute neuroretinitis (DUSN)
- •Malaria
- •Seasonal hyperacute panuveitis (SHAPU)
- •References
- •Postsurgical Uveitis
- •Acute bacterial endophthalmitis
- •Chronic bacterial endophthalmitis
- •Fungal endophthalmitis
- •Endogenous endophthalmitis
- •Lens-induced uveitis
- •Toxic anterior segment syndrome (TASS)
- •Laser-induced uveitis
- •Case 18-1
- •References
- •Anterior Uveitis
- •Epidemiology
- •Clinical description
- •Idiopathic anterior uveitis
- •Diagnostic workup
- •Treatment
- •HLA-B27–associated anterior uveitis
- •Epidemiology
- •Demographics and clinical findings
- •Etiology
- •HLA-B27–associated anterior uveitis with systemic disease
- •Ankylosing spondylitis
- •Etiology
- •Treatment
- •Reactive arthritis (Reiter’s syndrome)
- •Juvenile idiopathic arthritis
- •Diagnosis
- •Pathology
- •Differential diagnosis
- •Treatment and prognosis
- •Psoriatic arthropathy
- •Inflammatory bowel disease
- •Whipple’s disease
- •Disease associations
- •Fuchs’ heterochromic iridocyclitis
- •Etiology
- •Treatment and prognosis
- •Kawasaki disease
- •Tubulointerstitial nephritis and uveitis syndrome (TINU)
- •Pathogenesis
- •Glaucomatous cyclitic crisis
- •Schwartz syndrome
- •Anterior segment ischemia
- •Lens-induced uveitis
- •Anterior uveitis associated with AIDS
- •Other disease associations
- •References
- •Scleritis
- •Episcleritis
- •Scleritis
- •Disease associations
- •Other causes of scleritis
- •Diagnostic testing
- •Pathogenesis
- •Differential diagnosis
- •Treatment
- •References
- •Intermediate Uveitis
- •Epidemiology
- •Clinical manifestations
- •Prognosis
- •Differential diagnosis
- •Multiple sclerosis
- •Etiology
- •Treatment
- •Corticosteroids
- •Immunosuppressive agents
- •Surgery
- •Case 21-1
- •Case 21-2
- •References
- •Sarcoidosis
- •Epidemiology
- •Etiology
- •Clinical manifestations
- •Anterior uveitis
- •Posterior segment findings
- •Systemic involvement
- •Pathology
- •Diagnosis
- •Treatment
- •Case 22-1
- •References
- •Sympathetic Ophthalmia
- •Clinical appearance and prevalence
- •Classic presentation
- •Sequelae
- •Tests and immunologic characteristics
- •Dalen–fuchs nodules
- •Preservation of the choriocapillaris
- •Therapy
- •Corticosteroids
- •Immunosuppressive agents
- •Case 23-1
- •Case 23-2
- •References
- •Vogt–Koyanagi–Harada Syndrome
- •Clinical aspects
- •Systemic findings
- •Ocular findings
- •Course of disease
- •Laboratory tests, etiology, and histopathology
- •Antigen-specific and immune responses
- •Vogt–Koyanagi–Harada syndrome versus sympathetic ophthalmia
- •Therapy
- •Cataract extraction
- •Case 24-1
- •Case 24-2
- •References
- •Birdshot Retinochoroidopathy
- •Clinical manifestations
- •Ocular examination and ancillary clinical tests
- •Tests, histology and etiology
- •Therapy
- •Case 25-1
- •Case 25-2
- •References
- •Behçet’s Disease
- •Clinical manifestations
- •Oral aphthous ulcers
- •Skin lesions
- •Genital ulcers
- •Ocular disease
- •Retinal disease
- •Complications
- •Minor criteria
- •Arthritis
- •Vascular alterations
- •Neurologic involvement (neuro-Behçet’s disease)
- •Immunologic and histologic considerations
- •Role of T cells (but other cells count too!)
- •HLA typing and single nucleotide polymorphisms (SNPs)
- •Therapy
- •Systemic corticosteroids
- •Cytotoxic and antimetabolic agents
- •Colchicine
- •Interferon-α
- •Ciclosporin and tacrolimus (FK506)
- •Anti-TNF therapy (infliximab)
- •Other approaches
- •Case 26-1
- •Case 26-2
- •Case 26-3
- •References
- •Retinal Vasculitis
- •Clinical characteristics
- •Ocular vasculitic disorders without systemic disease
- •Eales’ disease
- •Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN syndrome)
- •Frosted branch angiitis
- •Scleritis
- •Ocular vasculitic disorders with systemic disease
- •Systemic lupus erythematosus
- •Polyarteritis nodosa
- •Wegener’s granulomatosis
- •Whipple’s disease
- •Inflammatory bowel disease
- •Autoantibodies to Sjögren’s syndrome A antigen
- •Retinal vein occlusion
- •Relapsing polychondritis
- •Viral diseases
- •Multiple sclerosis
- •Tuberculosis
- •Rheumatoid arthritis
- •Kikuchi–Fujimoto disease
- •Susac syndrome
- •Sweet syndrome
- •References
- •Serpiginous Choroidopathy
- •Clinical features
- •Pathology
- •Etiology
- •Differential diagnosis
- •Therapy
- •Case 28-1
- •Case 28-2
- •Case 28-3
- •References
- •White-Dot Syndromes
- •Multiple evanescent white-dot syndrome
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Multifocal choroiditis and panuveitis
- •Clinical findings
- •Punctate inner choroidopathy
- •Laboratory findings
- •Therapy
- •Acute retinal pigment epitheliitis
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Acute posterior multifocal placoid pigment epitheliopathy
- •Clinical findings
- •Etiology
- •Therapy
- •Subretinal fibrosis and uveitis syndrome
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Acute zonal occult outer retinopathy (AZOOR) and the azoor complex diseases
- •Case 29-1
- •Case 29-2
- •Case 29-3
- •References
- •Masquerade Syndromes
- •Intraocular lymphoma
- •Non-Hodgkin’s lymphoma of central nervous system
- •Diagnosis
- •Treatment
- •Systemic Non-Hodgkin’s lymphoma metastatic to eye
- •Lymphoid hyperplasia of uvea
- •Other malignant processes manifesting as uveitis
- •Paraneoplastic syndromes
- •Multiple sclerosis
- •Other nonmalignant conditions
- •References
- •Introduction
- •Age-related macular degeneration
- •Animal work
- •Animal laser model
- •Ccl2 and Ccr2 knockout model
- •Ccl2 and Cx3cr1 double knockout model
- •CEP induced AMD-like disease
- •Human data
- •Autoimmunity
- •Gene associations
- •Macrophages and other cells
- •Histopathology
- •The downregulatory immune environment
- •Should we consider immunotherapy?
- •Diabetic retinopathy
- •Diabetes and the immune process
- •Animal work
- •Human observations
- •Can we begin to think about immune therapy for diabetes and diabetic retinopathy?
- •Glaucoma
- •Autoantibodies and glaucoma
- •Cellular immunity and glaucoma
- •Can immune intervention help alter the course of glaucoma?
- •References
- •Index
insufficiency, mucocutaneous infections, and hypopara thyoridism, these patients can manifest diabetes, Sjögren’s syndrome, vitiligo, and uveitis.21
B cells
B cells make up the second broad arm of the lymphocyte immune response. Originating from the same pluripotential stem cell in the bone marrow as the T cell, the maturational process and role of the B cell are quite different. The term B cell originates from observations obtained from work with chickens, in which it was noted that antibody-producing cells would not develop if the bursa of Fabricius, a uniquely avian structure, was removed. The human equivalent appears to be the bone marrow. The B cell, under proper conditions, will develop into a plasma cell that is capable of secreting immunoglobulin. Therefore, its role is to function as the effector cell in humoral immunity. The unique characteristic of these cells is the presence of surface immunoglobulin on their cell membranes.
B-cells begin as a group of cells originating from stem cells designated as proor pre-B cells. The maturation process leading to a B cell is complex and not fully understood. What is clear is that various gene regions that control the B-cell’s main product, immunoglobulins, are not physically next to each other. Through a process of translocation these genes align themselves next to each other, excising intervening genes. IL-7 is an important factor in the maturation process. B cells can be activated by their interaction with CD4+ T cells that express on their surface class II MHC antigens and CD40 ligand. B-cell activation will cause these cells to divide, usually in the context of T-cell interaction and cytokines elaborated by the T cell, including IL-4, IL-5, IL-6, IL-17 and IL-2.
Subgroups of B cells have been described. Naive, conventional (B2) B cells are found. Another type, memory B cells, live for long periods, are readily activated, and will produce immunoglobulin (Ig) isotypes other than IgM (see next section). These cells presumably play an important role in the anamnestic response of the organism. This is the very rapid antigen-specific immune response that occurs when the immune system encounters an antigen to which it has already been sensitized. Another subgroup consists of B1 (CD5+) lymphocytes, whose characteristics overlap with those of other B cells but which appear to be derived from a separate lineage and are very long-lived. These cells produce IL-10 and have been associated with autoantibody production. Chronic lymphocytic leukemias often derive from B1 cells.
B cells initially express surface IgM and IgD simultaneously, with differentiation occurring only after appropriate activation. Five major classes of immunoglobulin are identified on the basis of the structure of their heavy chains: α, γ, µ, δ, and ε, corresponding to IgA, IgG, IgM, IgD, and IgE (Table 1-5). The structure of the immunoglobulin demonstrates a symmetry, with two heavy and two light chains uniformly seen in all classes except IgM and IgA (Fig. 1-6). The production of immunoglobulin usually requires T-cell participation. Many ‘relevant’ antigens are T-cell dependent, meaning that the addition of antigen to a culture of pure B cells will not induce immunoglobulin production. However, polyclonal B-cell activators, such as lipopolysaccharide,
Elements of the immune system
Table 1-5 Characteristics of human immunoglobulins |
|
|
|||
|
IgG |
IgA |
IgM |
IgE |
IgD |
Molecular weight |
150 |
150–300 |
900 |
190 |
180 |
(103) |
|
|
|
|
|
Heavy chain |
γ |
α |
µ |
− |
δ |
|
|
|
|
|
|
Subclass |
1,2,3,4 |
1,2 |
1,2 |
− |
− |
|
|
|
|
|
|
J chain |
− |
+ |
+ |
− |
− |
|
|
|
|
|
|
Crosses placenta |
+ |
− |
− |
− |
− |
|
|
|
|
|
|
Serum half-life |
21 |
6 |
5 |
2 |
3 |
(days) |
|
|
|
|
|
|
|
|
|
|
|
Complement |
+ |
− |
+ |
− |
− |
activation |
|
|
|
|
|
|
|
|
|
|
|
Serum |
110 |
25 |
10 |
0.001 |
0.3 |
concentration |
|
|
|
|
|
(mg/dL) |
|
|
|
|
|
IN EYE |
|
|
|
|
|
|
|
|
|
|
|
Conjunctiva |
Rich |
Rich |
Varies |
Varies |
Varies |
|
|
|
|
|
|
Cornea |
Moderate |
Moderate |
0 |
? |
0 |
|
|
|
|
|
|
Aqueous |
Low |
Low |
Low |
? |
0 |
|
|
|
|
|
|
Iris |
Low |
Low |
Low |
Varies |
Varies |
|
|
|
|
|
|
Choroid |
Rich |
Rich |
Rich |
Varies |
Varies |
|
|
|
|
|
|
Retina |
Low |
Low |
Low |
0 |
0 |
|
|
|
|
|
|
Vitreous |
− |
− |
− |
− |
− |
|
|
|
|
|
|
From Allansmith M. Unpublished data 1987. Used with permission.
Hypervariable region: antigen binding
VH
VL
Heavy Light chain chain
CH1
CL
Hinge region
Complement binding region
CH2
CH3
Fc portion
Cellular attachment
Figure 1-6. Structure of human IgG molecule.
9
Part 1 • Fundamentals
Chapter 1 Elements of the Immune System and Concepts of Intraocular Inflammatory Disease Pathogenesis
pokeweed mitogen, dextran, and the Epstein–Barr virus (as well as other viruses), have the capacity to directly induce B-cell proliferation and immunoglobulin production. For a primary immune response B cells will produce IgM, which binds complement. With time – and if they encounter these antigens again – B cells will switch immunoglobulin production to IgG, usually during the primary response. This immunoglobulin class switching, which requires a gene re arrangement, is inherent in the B cell and is partly controlled by lymphokines. IL-4 has been associated with a switch to express IgG (in mouse IgG1, in human IgG4) and IgE, whereas IFN-γ controls a switch to IgG2a and TGF-β to IgA.
Classes of Immunoglobulin
More IgA is made than any other immunoglobulin, much in the gut. IgG is the major circulating immunoglobulin class found in humans: it is synthesized at a very high rate and makes up about 75% of the total serum immunoglobulins. Plasma cells that produce IgG are found mainly in the spleen and the lymph nodes. Four subclasses of IgG have been identified in humans (G1–G4). G1 and G3 fix complement readily and can be transmitted to the fetus. The production of these subclasses is not random but reflects the antigen to which the antibody is being made. When doing tests in the serum or the chambers of the eye (aqueous or vitreous), we usually look at IgG production.
IgM is a pentamer made up of the typical antibody structure linked by disulfide bonds and J chains (Fig. 1-7). Only about one-fifteenth as much IgM as IgG is produced. Because of its size, it generally stays within the systemic circulation and, unlike IgG, will not cross the blood–brain barrier or the placenta. This antibody is expressed early on the surface of B cells. Therefore, initial antibody responses to exogenous pathogens, such as Toxoplasma gondii, are of this class. The observation of an IgM-specific antibody response helps to confirm a newly acquired infection. IgM has a complementbinding site and can mediate phagocytosis by fixing C3b, a component of the complement system.
One major role of both IgG and IgM is to interact with both effector cells and the complement system to limit the
invasion of exogenous organisms. These immunoglobulins aid effector cells through opsonization, which occurs by the antibody coating an invading organism and assisting the phagocytic process. The Fc portion of the antibody molecule then can readily interact with effector cells, such as macrophages, thereby helping effectively resolve the infection. Persons with deficiencies in IgG and IgM are particularly prone to infection by pyogenic organisms such as Streptococcus and Neisseria species. In addition, both of these antibodies will activate the complement pathway, inducing cell lysis by that mechanism as well.
IgA is the major extravascular immunoglobulin, although it comprises only about 10–15% of the intravascular total. Two isotypes of IgA are noted: IgA1 is more commonly seen intravascularly, whereas IgA2 is somewhat more prevalent in the extravascular space. The IgA-secreting plasma cells are found in the subepithelial spaces of the gut, respiratory tract, tonsils, and salivary and lacrimal glands. IgA is an important component to the defense mechanism of the ocular surface, being found in a dimer linked by a J chain, a polypeptide needed for polymerization. In addition, a secretory component, a unique protein with parts of its molecule having no homology to other proteins, is needed for the IgA to appear in the gut and outside vessels. The secretory component is produced locally by epithelial cells that then form a complex with the IgA dimer/J chain (Fig. 1-8). This new complex is internalized by mucosal cells and then released on the apical surface of the cell through a proteolytic process. The amount of IgA within the eye is quite small. IgA can fix complement through the alternate pathway, and can serve as an opsonin for phagocytosis. IgA appears to exert its major role by preventing entry of pathogens into the internal environment of the organism by binding with the infectious agent. It may also impede the absorption of potential toxins and allergens into the body. Further, it can induce eosinophil degranulation.
IgE is slightly heavier than IgG because its heavy chain has an additional constant domain. Mast cells and basophils
J chain
Secretory
piece
J chain
Figure 1-7. IgM pentamer with J chain.
Figure 1-8. IgA dimer with J chain and secretory piece.
10
- #28.03.202681.2 Mб0Ultrasonography of the Eye and Orbit 2nd edition_Coleman, Silverman, Lizzi_2006.pdb
- #
- #
- #
- #28.03.202621.35 Mб0Uveitis Fundamentals and Clinical Practice 4th edition_Nussenblatt, Whitcup_2010.chm
- #
- #
- #28.03.202627.87 Mб0Vaughan & Asbury's General Ophthalmology 17th edition_Riordan-Eva, Whitcher_2007.chm
- #
- #
- #
